Clinical trial NCT00820196: A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)
Official title: A Randomized, Double-Blind, Vehicle-controlled, Parallel Group, Dose-Ranging, Multi-center Study of the Efficacy and Safety of Nexagon® in the Treatment of Participants With Venous Leg Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Venous Ulcer
Keywords: Venous ulcer
Nexagon
CoDa
Lead sponsor: OcuNexus Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2009-01-12
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months. New treatments to help heal venous ulcers are urgently needed. Initial studies with a new drug product candidate called Nexagon® (developed by CoDa Therapeutics, Inc.) have shown improvements in healing when applied topically to a wound. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to venous leg ulcers in humans, and to obtain further information on the most appropriate dose or doses to apply. A proposed randomised controlled trial aims to further evaluate Nexagon® by randomly allocating (e.g., by the toss of a coin) 90 people with venous leg ulcers to Nexagon® (one of two different doses) or a vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed up for 12 weeks to evaluate ulcer healing.


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of venous leg ulceration
2. Ankle brachial index of \> 0.80 measured during screening or within three months prior to the Day -14 visit.
3. Reference ulcer area greater than 1 cm2 and less than 25 cm2
4. Reference ulcer present for at least 4 weeks
5. Have an ankle circumference of greater than 18 cm
6. Male of female patients aged 18 years or over
7. Able to tolerate effective compression bandaging
8. Patients able to walk independently with or without mobility aids
9. Able and willing to give informed consent
10. Able and willing to attend all follow up visits

Exclusion Criteria:

1. Significant change in ulcer size in the screening period screening period
2. Presence of a non-study ulcer within 2.0 cm of the reference ulcer
3. Wound bed with exposed bone, tendon or fascia
4. Patients with leg ulceration etiology other than venous insufficiency
5. Patients who require wheel chairs for normal mobility
6. Patients who have any ulcer (reference or non-reference) which shows signs of clinical infection
7. Patients who have any ulcer (reference or non-reference) positive for β-hemolytic streptococcus upon culture.
8. Patients who are unable to tolerate or comply with the standardized compression bandaging protocol specified in this protocol
9. Female patients who are pregnant or breastfeeding.
10. Patients who are currently taking:

    1. Pentoxifylline (Trental®)
    2. Immunosuppressive therapy
    3. Oral corticosteroid therapy or topical corticosteroid on the leg where the reference ulcer is located
    4. Growth factors (e.g. Regranex)
    5. Cell cultures or topical skin factors
11. Patients with:

    1. Renal insufficiency defined as an estimated GFR which is \< 30 mL/min/1.7m2
    2. Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range
    3. Hepatic insufficiency defined as total bilirubin \> 2 mg/dL or serum albumin \< 25 g/L
    4. HbA1c \> 8.5%
    5. Hemoglobin \< 10 g/dL
    6. Hematocrit \< 0.30
    7. Platelet count \< 100,000
12. Patients have had a myocardial infarction within the previous 6 months or patients with unstable angina pectoris
13. Patients with:

    1. Collagen vascular disease
    2. Severe rheumatoid arthritis
    3. Cellulitis or osteomyelitis
14. Patients who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment
15. Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study, e.g., known to abuse alcohol or drugs currently or to have psychological disorders that could affect follow-up care

Primary outcomes:
measure: Rate of reduction in the size of the reference ulcer from Day 0 to Day 28 as measured by photographic planimetry
Secondary outcomes:
measure: Complete healing of the treated Venous Leg Ulcer
measure: Reference ulcer wound healing as assessed by digital photographic planimetry
measure: Adverse Events
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Centre for Clinical Research
state: California
city: Stockton
country: United States
facility: Pacific Wound Center
state: California
city: Erie
country: United States
facility: Penn North Centers for Advanced Wound Care
state: Pennsylvania
city: Kittanning
country: United States
facility: Armstrong County Memorial Hospital
state: Pennsylvania
city: Auckland
country: New Zealand
facility: District Nursing and Leg Ulcer Service A+Links Home Health
city: Auckland
country: New Zealand
facility: Home Health Services Papakura
city: Auckland
country: New Zealand
facility: Waitemata District Health Board
city: Christchurch
country: New Zealand
facility: Nurse Maude
city: Dunedin
country: New Zealand
facility: Dunedin Hosptial
city: Hamilton
country: New Zealand
facility: Waikato Hospital
Study officials:
affiliation: OcuNexus Therapeutics, Inc.
name: Scott Bannan
role: STUDY_DIRECTOR
References: